Welcome to VIRTTU
VIRTTU Biologics is a clinical stage biotechnology company pioneering the development of oncolytic immunotherapies to treat cancer.
By remodelling a common Herpes Simplex virus (HSV) we have developed and patented a series of novel agents that target many forms of cancer effectively and have the potential to transform treatment.
SEPREHVIR®, our most advanced programme, is a unique cancer-destroying oncolytic immunotherapy that has the potential to radically change cancer therapy through its ability to:
(i) seek out and multiply only in cancer cells, destroying them while leaving healthy cells unaffected and;
(ii) stimulate a long lasting anti-tumour immune response.
We are now actively advancing the clinical development programme required to secure regulatory approval to market our lead programme, SEPREHVIR®, for use in cancer therapy.
In parallel, VIRTTU has an exciting development pipeline of next-generation oncolytic immunotherapies which build on the SEPREHVIR® concept by engineering additional therapeutic genes into the SEPREHVIR® backbone.
Hopeful monsters - Tumour Heterogeneity vs Oncolytic Viruses
The recent NCRI Cancer Conference provided a fascinating insight into the latest developments in understanding cancer development and treatment including the new understanding of clonal diversity of tumours and associated cancer genome evolution